Personalized Medicine for Pain Management




Pain Management Panel

Our pharmacogenetic testing panel provides pain management specialists reliable and actionable information to improve the lives of patients suffering from pain. Prescribers can now personalize drug therapy by identifying patients’ drug metabolizing phenotypes for improved efficacy and reduced adverse drug events (ADE).

The following assays are included in our pain panel:


Why Perform Pharmacogenetic Tests?

  • To identify the likelihood of an ADE.
    • An estimated 20-30% of pain patients have a genetic opioid metabolic defect (GOMD).1
    • 2.2 billion ADE occur yearly with over 100,000 cases resulting in death.2
  • To increase drug efficacy.
    • Only 58% of patients who take prescription pain medication receive relief.3
    • Inadequate pain relief is not the only result of poor pain management; prescription opioid pain relievers now account for more overdose deaths than heroine and cocaine combined.4
  • To improve patient compliance.
    • Knowledge of their genetic test results has been proven to make patients more likely to take medications as prescribed.5
  • To reduce healthcare costs by preventing ADE.
    • An estimated $136 billion is spent on treating ADE annually.2
    • Prescription opioid analgesics are among the most common causes of ADE.6

Simple, Informative Reports

We provide results in easy-to-read reports that are color coded to alert prescribers when a dose adjustment or alternative drug should be considered. (See Report Layout)

We also aid healthcare providers with therapeutic recommendations based on evidence supported by studies and clinical trials.

Covered by Medicare

Our tests are covered by Medicare and most major insurance companies. Our labs will work with a patient’s insurance company to obtain payment.



REFERENCES
  1. Tennant, Forest, MD, DPH, Making Practical Sense of Cytochrome P450, Practical Pain Management 10, no.4 (May 2010). Available online at http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/making-practical-sense-cytochrome-p450.
  2. U.S. Food and Drug Administration Development Resources, Preventable Adverse Drug Reactions: A Focus on Drug Interactions, Available online at http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm110632.htm.
  3. Peter D. Hart Research Associates, Americans Talk About Pain: A Survey Among Adults Nationwide (August 2003):7.
  4. Centers for Disease Control and Prevention, Vital Signs: Overdoses of Prescription Opioid Pain Relievers—United States, 1999-2008, Morbiidity and Mortality Weekly Report, (November 4, 2011), 60(43);1487-1492, Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm?s_cid=mm6043a4_w.
  5. Charland, Scott L. Pharm.D. Medco Research Institute, Patient knowledge of pharmacogenetic information improves adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial, (Poster presentation at the American College of Cardiology 61st Annual Scientific Session and Expo, Session Number 1258, Presentation Number 1258-376, Chicago, IL, March 26, 2012).
  6. The Joint Commission, Sentinel Event Alert Issue 49: Safe Use of Opioids in Hospitals, August 8, 2012:1. Available online at http://www,jointcommission.org/assets/1/18/SEA_49_opiods_8_2_12_final.pdf.


Contact your Diagnostics Express Sales Representative or Account Support at 888-702-6964 for more information about our services. You may also email info@myselfassessment.com with any questions.

All DNA assays are CLIA compliant and performed by AIBioTech LLC.